Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.
The company’s pipeline includes multiple product candidates at various stages of development. WP1066 is an immunotherapeutic compound designed to inhibit the STAT3 signaling pathway, which is implicated in the growth and survival of certain brain tumors and other malignancies. Annamycin is an anthracycline derivative engineered to overcome resistance mechanisms in acute myeloid leukemia (AML) with the goal of improving safety and efficacy. In addition, Moleculin is advancing WP1220, a broad-spectrum antiviral candidate targeting poxviruses and coronaviruses through inhibition of viral replication.
Headquartered in Houston, Texas, Moleculin Biotech collaborates with academic institutions and contract research organizations to conduct its preclinical and clinical studies. The company’s development programs include Phase 1 and Phase 2 clinical trials in the United States, with plans to initiate additional studies in international markets as regulatory approvals are secured. Such partnerships and trial sites enable Moleculin to advance its candidates efficiently through the clinical development pathway.
Founded in 2012, Moleculin Biotech is led by Walter Klemp, President and Chief Executive Officer, a veteran in the biotech industry with experience in drug development and corporate strategy. Under his leadership, the company continues to expand its research capabilities and global trial network, aiming to bring its innovative therapies to patients with critical oncological and viral diseases.
AI Generated. May Contain Errors.
